Invesco (NASDAQ: COLL) reports 1.59M Collegium shares (5.0%)

Rhea-AI Filing Summary

Invesco Ltd. reports beneficial ownership of 1,591,909 shares of Collegium Pharmaceutical Inc. common stock, representing 5.0% of the class. The filing states Invesco Ltd. has sole voting power for 1,490,397 shares and sole dispositive power for 1,591,909 shares.

Key Figures

Beneficial ownership: 1,591,909 shares Percent of class: 5.0% Sole voting power: 1,490,397 shares +3 more

6 metrics

Beneficial ownership 1,591,909 shares reported beneficially owned amount

Percent of class 5.0% percent of outstanding class reported

Sole voting power 1,490,397 shares shares with sole power to vote

Sole dispositive power 1,591,909 shares shares with sole power to dispose

CUSIP 19459J104 Collegium Common Stock identifier

Signature date 05/06/2026 filing signed by Global Head of Compliance

Key Terms

beneficially own, sole dispositive power, parent holding company, Schedule 13G

4 terms

beneficially own regulatory

"may be deemed to beneficially own 1,591,909 shares of the Issuer"

Beneficially own means having the economic rights and risks of a security—such as the right to receive dividends, sell the shares, or profit from price changes—whether or not your name appears on the official share register. Think of it like renting a car: you use it and reap the benefits even if the title lists someone else. Investors care because beneficial ownership determines who truly controls value, must be disclosed under securities rules, and can signal potential influence or trading activity that affects a stock’s price.

sole dispositive power regulatory

"Sole power to dispose or to direct the disposition of: 1,591,909"

Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.

parent holding company regulatory

"Invesco Ltd., in its capacity as a parent holding company to its investment advisers"

Schedule 13G regulatory

"Item 1. (a) Name of issuer: Collegium Pharmaceutical Inc"

A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/08/2026 - 10:17 AM Learn about SEC filing dates

FAQ

How many Collegium (COLL) shares does Invesco Ltd. report owning?

Invesco Ltd. reports beneficial ownership of 1,591,909 shares. The filing lists this as 5.0% of the class and shows sole dispositive power over all 1,591,909 shares and sole voting power over 1,490,397 shares.

What voting and dispositive powers does Invesco Ltd. have in the COLL filing?

Invesco Ltd. has sole voting power for 1,490,397 shares and sole dispositive power for 1,591,909 shares. The filing shows no shared voting or dispositive power for these holdings.

Does the Schedule 13G indicate ownership is held for clients or the firm?

The filing states shares are held of record by clients of Invesco Ltd. Invesco Ltd. is reported in a parent capacity to its investment advisers and may be deemed to beneficially own the shares on behalf of clients.

When was the Schedule 13G for Invesco Ltd. signed for Collegium (COLL)?

The signature on the filing is dated 05/06/2026. The cover references 03/31/2026 as a reporting date; the signature is by Robert R. Leveille, Global Head of Compliance for Invesco Ltd.

Are any other entities identified as holding the securities on behalf of Invesco Ltd.?

The filing names Invesco Advisers, Inc. and Invesco Capital Management LLC as relevant subsidiaries. It states no single shareholder of the fund has greater than 5% economic ownership and lists clients as record holders.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Collegium Pharmaceutical Inc

(Name of Issuer)

Common Stock

(Title of Class of Securities)

19459J104

(CUSIP Number)

03/31/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 19459J104

1

Names of Reporting Persons

Invesco Ltd.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

BERMUDA

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 1,490,397.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 1,591,909.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

1,591,909.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.0 %

12

Type of Reporting Person (See Instructions)

HC, IA

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Collegium Pharmaceutical Inc
(b)	Address of issuer's principal executive offices: 100 Technology Center Drive, Suite 300, Stoughton, MA 02072
Item 2.
(a)	Name of person filing: Invesco Ltd. ("Invesco Ltd.")
(b)	Address or principal business office or, if none, residence: 1331 Spring Street NW, Suite 2500, Atlanta, GA 30309
(c)	Citizenship: Bermuda
(d)	Title of class of securities: Common Stock
(e)	CUSIP Number(s): 19459J104
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: Invesco Ltd., in its capacity as a parent holding company to its investment advisers, may be deemed to beneficially own 1,591,909 shares of the Issuer which are held of record by clients of Invesco Ltd.
(b)	Percent of class: 5.0 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 1,490,397
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 1,591,909
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. However, no one individual has greater than 5% economic ownership. The shareholders of the Fund have the right to receive or the power to direct the receipt of dividends and proceeds from the sale of securities listed above.
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary. Invesco Advisers, Inc. Invesco Capital Management LLC
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Invesco Ltd.

Signature:	Robert R. Leveille
Name/Title:	Global Head of Compliance
Date:	05/06/2026